Menu

CME Corner

Program Detail

Release Date: March-17-17
Credit Expiration Date: March-17-18

Faculty

Presenter
William J. Sandborn, MD
Professor of Medicine
Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California San Diego
UC San Diego Health System
La Jolla, CA

Additional Content Development Faculty 
Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Division of Gastroenterology and Hepatology
Northwestern University Feinberg School of Medicine
Chicago, IL

Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Lawrence J. Brandt, MD
(CCME reviewer)
Professor, Department of Medicine (Gastroenterology & Liver Diseases)
Albert Einstein College of Medicine
Bronx, NY 

Credit Hours

1.0 AMA PRA Category 1 Credit

Medium

Online Presentation

Program Description

IBD is a chronic gastrointestinal condition characterized by recurring disease activity. Treatment approaches for IBD vary depending on disease type and severity and patient risk profile. An accurate diagnosis combined with severity and risk assessments at appropriate intervals are essential for optimal management of IBD. Despite guidance from AGA and ACG, however, clinicians demonstrate considerable variation in their approaches to both risk assessment and care for patients with IBD. This activity will address the knowledge and practice gaps identified in our needs assessment related to severity and risk assessment, appropriate treatment, and patient communication.

Program Developer/Facilitator

This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.

Target Audience

Gastroenterologists and other clinicians involved in the management of patients with IBD including nurse practitioners (NPs), physician assistants (PAs), and nurses.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Review the approaches to risk and severity assessment for patients with IBD, as it relates to treatment decision-making.
  2. Discuss the treatment strategies for the management of patients with high-risk IBD, including the benefits and safety profile of biologic therapy.
  3. Discuss the guideline recommendations and quality measures related to preventative care and screening needs in patients with IBD.
  4. Describe practical approaches to patient engagement to optimize shared treatment decision-making.

Disclosures

The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.

FACULTY DISCLOSURES
William J. Sandborn, MD
Consultant: Janssen, AbbVie, UCB Pharma, Takeda, Pfizer, Genentech, Amgen, Medimmune, Celgene
Speakers Bureau: Janssen
Contracted Research: Janssen, AbbVie, Takeda, Pfizer, Genentech, Amgen, Celgene

Stephen B. Hanauer, MD
Consultant: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Genentech, Hospira, Janssen, Lilly, Merck, Novartis, Pfizer, Prometheus, Receptos, Salix, Seres Health, Shire, Takeda, Tigenex, UCB
Speakers Bureau: AbbVie, Janssen, Takeda
Contracted Research: AbbVie, Amgen, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB

Adam S. Cheifetz, MD
Consultant: Janssen, Pfizer, Samsung

Lawrence J. Brandt, MD (CCME reviewer)
Nothing to disclose.

The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests relative to this CME activity.

Credit Statements

ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Albert Einstein College of Medicine, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Certificate Fee

$0.00

Disclaimer

Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education.

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, or Takeda Pharmaceuticals U.S.A., Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS